26March

Novo Nordisk has decided to resubmit the New Drug Applications of Tresiba® and R ... Read more

25March

Novo Nordisk A/S: Novo Nordisk completes phase 3a trials comparing faster-acting ... Read more

23March

Novo Nordisk A/S: Saxenda® approved in Europe for the treatment of obesity ... Read more

19March

Resolutions from the Annual General Meeting of Novo Nordisk A/S ... Read more

26March

Novo Nordisk has decided to resubmit the New Drug Applications of Tresiba® and R ... Read more

25March

Novo Nordisk A/S: Novo Nordisk completes phase 3a trials comparing faster-acting ... Read more

23March

Novo Nordisk A/S: Saxenda® approved in Europe for the treatment of obesity ... Read more

23March

Novo Nordisk A/S - Share repurchase programme ... Read more

30April

Financial statement for the first three months of 2015,

07May

Deutsche Bank Healthcare Conference, Boston

12May

Merrill Lynch Conference, Las Vegas

20May

Citi Swiss Healthcare Investor Day, Zurich

 

 

 

Investors

 
Share information


Take an advanced view of the Novo Nordisk share

Read more

 
IR material


Download relevant Investor Relations material

Read more

 
Financial results


See the full-year 2014 financial statement

Read more



Novo Nordisk at a glance


Read about Novo Nordisk – A focused healthcare company

Read more



Private shareholders


See relevant content for private investors

Read more



Annual report


Download the Novo Nordisk Annual Report

Read more



Contacts


Kasper Roseeuw Poulsen

Head of Investor Relations
Mobile: +45 3079 4303
e-mail: krop@novonordisk.com

Read more



Subscriptions


Sign up and follow Novo Nordisk Investors Relations



Recent event


See info on the conference call on the US Saxenda® launch